KNSA insider buying and SEC filings, explained
Kiniksa Pharmaceuticals International, plc · CIK 1730430
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- Fiscal year end
- Dec 31
- Former names
- Kiniksa Pharmaceuticals, Ltd.
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$299K
Planned sales (10b5-1)
$110.3M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 30–Nov 3, 2026 | Planned (10b5-1) | Sanj K Patel (CEO and Director) sold 402,494 shares indirectly (by trust) between Oct 30 and Nov 3 at about $92.92 ($37.4M), marked as a 10b5-1 plan trade. Holdings by trust down 34% to 780,037 shares. | SEC filing Filed Nov 3, 2026, 7:30 PM ET |
| Nov 2, 2026 | Planned (10b5-1) | Mark Ragosa (CFO) sold 36,783 shares at about $92.16 ($3.4M), marked as a 10b5-1 plan trade. Holdings down 64% to 20,854 shares. | SEC filing Filed Nov 3, 2026, 6:32 PM ET |
| Oct 30–Nov 2, 2026 | Planned (10b5-1) | John F. Paolini (Chief Medical Officer) sold 96,000 shares between Oct 30 and Nov 2 at about $93.09 ($8.9M), marked as a 10b5-1 plan trade. Holdings down 58% to 69,922 shares. | SEC filing Filed Nov 3, 2026, 6:28 PM ET |
| Oct 30–Nov 2, 2026 | Planned (10b5-1) | Ross Moat (President / COO) sold 103,585 shares between Oct 30 and Nov 2 at about $92.93 ($9.6M), marked as a 10b5-1 plan trade. Holdings down 91% to 10,294 shares. | SEC filing Filed Nov 3, 2026, 6:27 PM ET |
| Oct 30, 2026 | Planned (10b5-1) | Michael R Megna (Chief Accounting Officer) sold 36,260 shares at about $94.43 ($3.4M), marked as a 10b5-1 plan trade. Holdings down 74% to 12,697 shares. | SEC filing Filed Nov 3, 2026, 6:26 PM ET |
| Sep 3, 2026 | Planned (10b5-1) | Michael R Megna (Chief Accounting Officer) sold 4,600 shares at $80.30 ($369K), marked as a 10b5-1 plan trade. Holdings down 14% to 29,062 shares. | SEC filing Filed Sep 3, 2026 |
| Jul 29, 2026 | Sale | G Bradley Cole (Director) sold 3,673 shares at $81.43 ($299K). Holdings down 24% to 11,672 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jul 31, 2026 |
| May 1, 2026 | Planned (10b5-1) | John F. Paolini (Chief Medical Officer) sold 58,424 shares at about $53.71 ($3.1M), marked as a 10b5-1 plan trade. Holdings down 47% to 65,623 shares. | SEC filing Filed May 5, 2026 |
| May 1, 2026 | Planned (10b5-1) | Sanj K Patel (CEO and Director) sold 48,565 shares at about $54.02 ($2.6M), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed May 1, 2026 |
| Apr 28–30, 2026 | Planned (10b5-1) | Sanj K Patel (CEO and Director) sold 508,339 shares between Apr 28 and Apr 30 at about $51.96 ($26.4M), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Apr 30, 2026 |
| Apr 28, 2026 | Planned (10b5-1) | Barry D Quart (Director) sold 13,099 shares at about $50.10 ($656K), marked as a 10b5-1 plan trade. Holdings down 51% to 12,546 shares. | SEC filing Filed Apr 29, 2026 |
| Apr 9, 2026 | Planned (10b5-1) | Ross Moat (President / COO) sold 1,703 shares at $46.69 ($80K), marked as a 10b5-1 plan trade. Holdings down 12% to 12,029 shares. | SEC filing Filed Apr 13, 2026 |
| Apr 9, 2026 | Planned (10b5-1) | Michael R Megna (Chief Accounting Officer) sold 6,625 shares at $46.69 ($309K), marked as a 10b5-1 plan trade. Holdings down 19% to 27,418 shares. | SEC filing Filed Apr 13, 2026 |
| Apr 6, 2026 | Planned (10b5-1) | Ross Moat (President / COO) sold 2,367 shares at $48.58 ($115K), marked as a 10b5-1 plan trade. Holdings down 16% to 12,029 shares. | SEC filing Filed Apr 8, 2026 |
| Apr 6, 2026 | Planned (10b5-1) | Sanj K Patel (CEO and Director) sold 7,278 shares at about $50.01 ($364K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Apr 8, 2026 |
| Apr 6, 2026 | Planned (10b5-1) | Barry D Quart (Director) sold 6,901 shares at about $50.00 ($345K), marked as a 10b5-1 plan trade. Holdings down 35% to 12,546 shares. | SEC filing Filed Apr 8, 2026 |
| Mar 9, 2026 | Planned (10b5-1) | Mark Ragosa (CFO) sold 36,722 shares at about $45.92 ($1.7M), marked as a 10b5-1 plan trade. Holdings down 75% to 12,086 shares. | SEC filing Filed Mar 11, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | John F. Paolini (Chief Medical Officer) sold 40,000 shares at about $44.82 ($1.8M), marked as a 10b5-1 plan trade. Holdings down 39% to 61,324 shares. | SEC filing Filed Mar 4, 2026 |
| Feb 10–12, 2026 | Planned (10b5-1) | Barry D Quart (Director) sold 2,800 shares between Feb 10 and Feb 12 at $45.00 ($126K), marked as a 10b5-1 plan trade. Holdings down 18% to 12,546 shares. | SEC filing Filed Feb 12, 2026 |
| Feb 9, 2026 | Planned (10b5-1) | Mark Ragosa (CFO) sold 17,845 shares at about $43.28 ($772K), marked as a 10b5-1 plan trade. Holdings down 60% to 12,086 shares. | SEC filing Filed Feb 11, 2026 |
| Feb 2–4, 2026 | Planned (10b5-1) | Barry D Quart (Director) sold 15,960 shares between Feb 2 and Feb 4 at about $45.22 ($722K), marked as a 10b5-1 plan trade. Holdings down 56% to 12,546 shares. | SEC filing Filed Feb 4, 2026 |
| Jan 8, 2026 | Planned (10b5-1) | Mark Ragosa (CFO) sold 12,000 shares at about $41.89 ($503K), marked as a 10b5-1 plan trade. Holdings down 39% to 19,086 shares. | SEC filing Filed Jan 9, 2026 |
| Dec 15, 2025 | Planned (10b5-1) | Eben Tessari (President / COO) sold 12,048 shares at about $41.56 ($501K), marked as a 10b5-1 plan trade. Holdings down 42% to 16,666 shares. | SEC filing Filed Dec 17, 2025 |
| Dec 15, 2025 | Planned (10b5-1) | Barry D Quart (Director) sold 20,129 shares at about $41.51 ($836K), marked as a 10b5-1 plan trade. Holdings down 62% to 12,546 shares. | SEC filing Filed Dec 17, 2025 |
| Dec 8, 2025 | Planned (10b5-1) | Mark Ragosa (CFO) sold 42,841 shares at about $41.49 ($1.8M), marked as a 10b5-1 plan trade. Holdings down 58% to 31,086 shares. | SEC filing Filed Dec 10, 2025 |
| Nov 26, 2025 | Planned (10b5-1) | Eben Tessari (President / COO) sold 200 shares at $42.89 ($9K), marked as a 10b5-1 plan trade. Holdings down 1% to 22,714 shares. | SEC filing Filed Dec 1, 2025 |
| Nov 17, 2025 | Planned (10b5-1) | Eben Tessari (President / COO) sold 12,470 shares at about $41.24 ($514K), marked as a 10b5-1 plan trade. Holdings down 35% to 22,714 shares. | SEC filing Filed Nov 19, 2025 |
| Nov 12, 2025 | Planned (10b5-1) | Mark Ragosa (CFO) sold 19,900 shares at about $40.94 ($815K), marked as a 10b5-1 plan trade. Holdings down 39% to 31,086 shares. | SEC filing Filed Nov 14, 2025 |
| Oct 31, 2025 | Planned (10b5-1) | John F. Paolini (Chief Medical Officer) sold 82,542 shares at about $37.14 ($3.1M), marked as a 10b5-1 plan trade. Holdings down 57% to 61,324 shares. | SEC filing Filed Nov 4, 2025 |
54 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow KNSA in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.